United Therapeutics (UTHR) Revenue (2009 - 2026)
United Therapeutics (UTHR) posted Revenue of $781.5 million for Q1 2026, down 1.1% sequentially from $790.2 million in Q4 2025, and down 1.62% YoY from $794.4 million in Q1 2025.
United Therapeutics (UTHR) Revenue (2009 - 2026) Analysis & Trends
United Therapeutics has reported Revenue for 18 years, with the latest figure at $781.5 million in Q1 2026.
- Quarterly Revenue fell 1.62% year-over-year to $781.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 5.87% YoY) and the FY2025 annual result came in at $3.2 billion, up 10.61% from the prior year.
- Revenue fell to $781.5 million in Q1 2026 per UTHR's latest filing, from $790.2 million in the prior quarter.
- Over five years, Revenue peaked at $799.5 million in Q3 2025 and troughed at $461.9 million in Q1 2022.
- A 5-year average of $653.3 million and a median of $677.7 million in 2024 frame the typical range for Revenue.
- The sharpest annual moves came in 2024 and 2026: Revenue jumped 33.7% in 2024, then declined 1.62% in 2026.
- Over 5 years, Revenue stood at $491.5 million in 2022, then rose by 25.07% to $614.7 million in 2023, then increased by 19.72% to $735.9 million in 2024, then rose by 7.38% to $790.2 million in 2025, then declined by 1.1% to $781.5 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $781.5 million, $790.2 million, and $799.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 4.14 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 2.47 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 7.65 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 783.30 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 3.76 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 959.00 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 106.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 1.37 Bn |
| 10 | HUTCHMED (China) | 10.92 Bn | 9.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 783.30 Mn |
| Mar 31, 2026 | 781.50 Mn |
| Dec 31, 2025 | 790.20 Mn |
| Sep 30, 2025 | 799.50 Mn |
| Jun 30, 2025 | 798.60 Mn |
| Mar 31, 2025 | 794.40 Mn |
| Dec 31, 2024 | 735.90 Mn |
| Sep 30, 2024 | 748.90 Mn |
| Jun 30, 2024 | 714.90 Mn |
| Mar 31, 2024 | 677.70 Mn |
| Dec 31, 2023 | 614.70 Mn |
| Sep 30, 2023 | 609.40 Mn |
| Jun 30, 2023 | 596.50 Mn |
| Mar 31, 2023 | 506.90 Mn |
| Dec 31, 2022 | 491.50 Mn |
| Sep 30, 2022 | 516.00 Mn |
| Jun 30, 2022 | 466.90 Mn |
| Mar 31, 2022 | 461.90 Mn |
| Dec 31, 2021 | 415.20 Mn |
| Sep 30, 2021 | 444.70 Mn |